Can a Parkinson's drug protect eyes in diabetes?
NCT ID NCT05132660
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether levodopa, a drug used for Parkinson's, can slow blood vessel changes in the eyes of people with diabetes. Researchers will give the drug or a placebo to 244 patients with early diabetic retinopathy and measure retinal electrical activity and imaging over time. The goal is to see if levodopa can delay vision loss.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Levodopa (Sinemet CR)
- What this could lead to
- If it works, this could point toward a treatment to slow diabetic retinopathy and preserve vision.
- What could go wrong
- This is a very early, small trial. It may not show benefit, and levodopa can cause side effects like nausea or dizziness.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIABETIC RETINOPATHY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Atlanta VA Medical and Rehab Center, Decatur, GA
Decatur, Georgia, 30033-4004, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- AI eye doctor: could software catch diabetic blindness sooner?
- Can eye scans reveal hidden clues about diabetes damage?
- AI could predict which eye treatments work best for Diabetes-Related vision loss
- New eye drug aims to restore vision in Diabetes-Related swelling
- New eye drug aims to restore vision in Diabetes-Related swelling
- Eye scans could spot Diabetes-Related vision damage years early